Wellington Management Group LLP Invests $1.95 Million in Avalo Therapeutics, Inc. $AVTX

Key Points

• Wellington Management initiated a $1.95 million position in Avalo Therapeutics during the second quarter, buying 105,261 shares. Institutional investors and hedge funds collectively own 87.06% of AVTX.
• Analysts maintain a generally positive outlook, with 12 Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $45.10. However, several firms recently lowered their targets.
• AVTX opened at $17.18 after declining 5.7%, while Avalo reported a quarterly loss of $0.83 per share—$0.25 worse than estimates. Insiders own 4.46% of the company, and one insider recently sold shares under a pre-arranged trading plan.

Wellington Management Group LLP bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 105,261 shares of the company's stock, valued at approximately $1,945,000. Wellington Management Group LLP owned 0.20% of Avalo Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. UBS Group AG lifted its position in Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company's stock worth $8,677,000 after purchasing an additional 432,608 shares during the period. Renaissance Technologies LLC increased its holdings in Avalo Therapeutics by 556.4% in the 1st quarter. Renaissance Technologies LLC now owns 120,114 shares of the company's stock valued at $1,793,000 after buying an additional 101,814 shares during the period. Seven Fleet Capital Management LP increased its holdings in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company's stock valued at $8,568,000 after buying an additional 510,540 shares during the period. DV Trading LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $5,376,000. Finally, Sei Investments Co. acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $849,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the business's stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares of the company's stock, valued at approximately $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,129 shares of company stock valued at $59,680 in the last quarter. Company insiders own 4.46% of the company's stock.

Analyst Upgrades and Downgrades

AVTX has been the topic of several analyst reports. Citizens Jmp reduced their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Thursday, May 14th. HC Wainwright lowered their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Bank of America assumed coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $45.10.

Avalo Therapeutics Trading Down 5.7%

AVTX stock opened at $17.18 on Friday. The firm has a 50-day moving average price of $19.13 and a 200-day moving average price of $17.06. Avalo Therapeutics, Inc. has a 12 month low of $9.54 and a 12 month high of $24.27. The stock has a market capitalization of $921.36 million, a P/E ratio of -3.93 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts predict that Avalo Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.